Cognition reaches FDA alignment on a pivotal zervimesine trial for dementia with Lewy bodies. The Phase 3 study has not started yet.
#Dementia #FDA #Biotech
Disclaimer: This is NOT a financial advice
Cognition reaches FDA alignment on a pivotal zervimesine trial for dementia with Lewy bodies. The Phase 3 study has not started yet. #Dementia #FDA #Biotech Disclaimer: This is NOT a financial advice
0 vue
Publié le 13/11/2026 09:10
0:39
Cognition reaches FDA alignment on a pivotal zervimesine trial for dementia with Lewy bodies. The Phase 3 study has not started yet.
#Dementia #FDA #Biotech
Disclaimer: This is NOT a financial advice
biotechstockdaily.com/fda-clinical...